Please login to the form below

Not currently logged in
Email:
Password:

Provenge

This page shows the latest Provenge news and features for those working in and with pharma, biotech and healthcare.

Valeant uncouples Dendreon and skincare brands to cut debt

Valeant uncouples Dendreon and skincare brands to cut debt

Agrees deals worth $2.1bn with L’Oreal and Sanpower Group. Dendreon's Provenge cancer vaccine. ... Meanwhile, the Dendreon deal comes two years after Valeant paid around $300m for the business, which sells Provenge, an autologous cellular immunotherapy

Latest news

More from news
Approximately 9 fully matching, plus 20 partially matching documents found.

Latest Intelligence

  • Assessing the risks in annuity pricing models Assessing the risks in annuity pricing models

    Three others (ChondroCelect, PROVENGE and Glybera) were withdrawn, partly due to challenges associated with reimbursement.

  • Cancer immunotherapy: What's on the horizon? Cancer immunotherapy: What's on the horizon?

    Vaccines. While the first therapeutic cancer vaccines have reached the market, eg Dendreon’s Provenge and Antigenics’ Oncophage, commercially they haven’t yet made much impact and the pipeline has been

  • Deal Watch January 2017 Deal Watch January 2017

    Bringing in an additional $819.9m in cash, Valeant also sold its equity interest in Dendreon (manufacturer of Provenge, a personalised immunotherapy) to the Sanpower Group.

  • Medius Deal Watch table for February 2015 Medius Deal Watch table for February 2015

    Corporate acquisition. 400. Dendreon/ Valeant Pharmaceuticals. PROVENGE (sipuleucel-T) and other assets - prostate cancer.

  • Pharma deals in February 2015 Pharma deals in February 2015

    This month saw the deadline, highlighted in January's Deal Watch, for Valeant to acquire Dendreon, and more specifically the dendritic cell, prostate cancer vaccine Provenge (sipuleucel-T), come and go.

More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.

Latest appointments

  • Dendreon appoints new R&D lead Dendreon appoints new R&D lead

    The appointment comes at a time when the Californian biopharma drives to expand the use of Provenge (sipuleucel-T). ... Bruce’s valuable background leading major medical organisations makes him the ideal fit to accelerate our R&D programme and oversee

  • Dendreon CEO to step down Dendreon CEO to step down

    John Johnson to leave next summer as Provenge sales stall. Dendreon has announced that CEO John Johnson will leave the company in August next year. ... According to the company's financial report, sales of Provenge declined from $325m in 2012 to $286m in

  • AP Pharma appoints Dendreon’s Jesse Hollingsworth to lead sales AP Pharma appoints Dendreon’s Jesse Hollingsworth to lead sales

    prostate cancer vaccine Provenge.

  • Lindsay Rocco to lead corporate communications at Dendreon Lindsay Rocco to lead corporate communications at Dendreon

    The US biotech, which markets prostate cancer vaccine Provenge (sipuleucel-T), said Rocco will be responsible for all communications functions of the company, reporting directly to chair, president and CEO John

More from appointments
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Aptus Health

Aptus Health is dedicated to advancing health engagement. The company offers end-to-end digital health engagement solutions spanning all areas of...

Latest intelligence

Language barriers: Obesity has become a loaded word
...
Spotlight interview: 15 minutes on digital in medical communications
Gemma Allen, Head of Digital Communications, OPEN Health takes 15 minutes to answer some key questions on digital in medical communications...
Generating data on long-term outcomes with gene and other advanced therapies
Gene therapy and advanced cell-based therapies offer patients hope and the potential to make them ‘chronically well’....

Infographics